Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

April 6, 2018: By Joan McKenna

The Delaware Supreme Court has ruled in favor of Alcon in a suit brought by Elenza, a Virginia-based medical device company, over an electroactive intraocular lens (EAIOL) for cataract patients.

The court, ruling on an appeal by Elenza, said March 20 that it agreed with Delaware’s Superior Court that Elenza failed to support its claim that Texas-based Alcon improperly used or disclosed any of Elenza’s alleged trade secrets.

From 2008 to 2010, Elenza worked on EAIOL technology that used electric power and changes in eye pupil size to “trigger” focus. Alcon was also exploring EAIOL lenses. The two companies decided to work together.

On May 24, 2010, Elenza and Alcon signed a non-disclosure agreement, followed by a stock purchase agreement that included development milestones.

In December 2011, Alcon decided that Elenza had not met the first milestone, and the companies parted ways in July 2012, though they remained under the contractual obligations of the NDA.

Elenza was unable to find another investor and ceased operations in August 2013.

That same month, Alcon filed a patent application for an electro-active lens that automatically accommodates based on the movements of the eye’s ciliary muscle.

On March 20, 2014, Elenza filed a complaint against Alcon and claimed breach of contract and misappropriation of trade secrets.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023